Articles > Popular publications > Business Wire press releases > April-June 2006 > Wednesday, June 7

Article: Abraxis BioScience Receives Approval in Canada for ABRAXANE to Treat Metastatic Breast Cancer Including First-Line Disease.

Article from:
Business Wire
Article date:
June 7, 2006
Copyright

LOS ANGELES & TORONTO -- Abraxis BioScience, Inc. (NASDAQ:ABBI):

Newly Released Data From Pivotal Trial Demonstrate ABRAXANE Significantly Improves Progression-Free Survival and Time to Tumor Progression and Nearly Doubles the Response Rate Versus Taxol

Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced it has received approval for ABRAXANE(TM) for Injectable Suspension (paclitaxel powder for injectable suspension) (nanoparticle, albumin-bound (nab) paclitaxel) from the Therapeutic Products Directorate of Health Canada under a Notice of Compliance for the treatment of metastatic breast cancer in ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: Abraxis BioScience and Specialised Therapeutics ...
Cancer Weekly;  November 4, 2008 ;     700+ words ... ... countries (see also Abraxis BioScience, Inc ... with metastatic breast cancer," said Patrick ... Executive Officer of Abraxis BioScience. "In the US ... for metastatic breast cancer. Developed using Abraxis BioScience's proprietary ...

Article: Abraxis BioScience Announces Approval to Market ...
Cancer Weekly;  July 29, 2008 ;     700+ words ... ... with metastatic breast cancer," said Patrick ... Executive Officer of Abraxis BioScience. "With cancer ... incidence of breast cancer in China has ... for metastatic breast cancer. Developed using Abraxis BioScience's proprietary ...

Article: Biocon and Abraxis BioScience Launch ABRAXANE in ...
Business Wire;  July 18, 2008 ;     700+ words ... ... company, and Abraxis BioScience, Inc. (NASDAQ ... treatment of breast cancer after failure ... Executive Officer of Abraxis BioScience. "In addition ... treatment of breast cancer. This unique ... treatment in breast cancer." Ms. Mazumdar ... Development at ...

Article: Abraxis BioScience to Present Data from Six Studies ...
Business Wire;  December 11, 2006 ;     700+ words ... ... line Metastatic Breast Cancer Poster Presentations ... Highlight Treatment of Breast Cancer with ABRAXANE in ... Regimens LOS ANGELES -- Abraxis BioScience, Inc. (NASDAQ ... Annual San Antonio Breast Cancer Symposium, December ...

Article: Abraxis BioScience Announces Approval to Market ...
Business Wire;  April 9, 2008 ;     700+ words ... ... ANGELES -- Abraxis BioScience, Inc ... treatment of breast cancer after failure ... metastatic breast cancer. We look ... officer of Abraxis BioScience. "This approval ... metastatic breast cancer. The Korean ...

Article: Abraxis to study nab-docetaxel in prostate and breast ...
Pharma Marketletter;  April 2, 2007 ;     700+ words ...Abraxis BioScience, an integrated, global, USA ... cancer, as well as in metastatic breast cancer. The trials, which are scheduled ... Administration approval in metastatic breast cancer indications (Marketletter passim ...

Article: Abraxis Bioscience Launches ABRAXANE[R] in China ...
Blood Weekly;  July 2, 2009 ;     700+ words ...Abraxis Bioscience, Inc. (NASDAQ ... with metastatic breast cancer. In a global ... treatment of breast cancer after failure ... chemotherapy (see also Abraxis Bioscience, Inc ... with metastatic breast cancer," said Prof ...

Article: Abraxis Bioscience Releases Abraxane in China for ...
Health & Beauty Close-Up;  June 15, 2009 ;     700+ words ...Abraxis Bioscience, Inc ... metastatic breast cancer, the company ... advanced breast cancer now have ... Manager of Abraxis BioScience China and ... treatment of breast cancer," said ... and CMO of Abraxis BioScience Beijing Representative ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives